Divestment

Zealand Pharma

Zealand Pharma developed peptide drugs for type 2 diabetes.

Responsible partner
News

Key Facts

Sector: Life Sciences
Country: Denmark
Fund: LSP 3
Entry: 2005
Exit: 2013

Responsible Partner

René R. Kuijten

René R. Kuijten

Partner, Head of EQT Life Sciences

News

September 30, 2025
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
September 16, 2025
EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion
June 11, 2025
EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio
June 9, 2025
EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray

Do You Want to Know More?

We are eager to explore how we can achieve great things together.